Blueweave
Viral Vector Manufacturing Market

Viral Vector Manufacturing Market

Viral Vector Manufacturing Market - Global Size, Share, Trend Analysis, Opportunity and Forecast Report, 2018–2028, Segmented By Type (Adenoviral Vector, Adeno-Associated Viral Vector, Lentiviral Vector, Retroviral Vector, Others), By Disease (Cancer, Genetic Disorder, Infectious Disease, Others), By Application (Gene Therapy, Vaccinology, Others), By End User (Pharmaceutical and Biopharmaceutical Companies, Research Institutes, Others), By Region (North America, Europe, Asia Pacific, Latin America, Middle East and Africa)

  • Published Date: September 2022
  • Report ID: BWC22373
  • Available Format: PDF
  • Page: 146

Report Overview

Spurring demand for discovering efficient therapeutics for various types of cancer is expected to expand the Global Viral Vector Manufacturing Market at a robust growth rate during the forecast period.

Global Viral Vector Manufacturing Market - Overview

Global Viral Vector Manufacturing Market size was valued at USD 447.2 million in 2021. During the forecast period between 2022 and 2028, the global viral vector manufacturing market size to grow at a CAGR of 19.3% to reach a value of USD 1,523.6 million by 2028. Increased incidences of chronic diseases and disorders, growing investments in the development of gene therapies, efficiency of viral vectors in the delivery of gene therapies, and continuous research into viral vector-based gene & cell therapies are major growth drivers for global viral vector manufacturing market.

Global Viral Vector Manufacturing Market - Industry Trends and Market Forecast

Genetic material can be delivered into cells via viral vectors. For transferring their DNA inside the cells they infect, viruses have evolved unique transport mechanisms. The viral vectors that can be used to introduce genetic material into the genetic makeup of cells include retroviruses, adenoviruses, lentiviruses, herpes simplex viruses, and others.

Cancer, a sub-segment in the disease segment of the market, is anticipated to expand more quickly. Modern healthcare facilities and the rise in cancer incidence around the world are important factors driving the market's expansion. Viral vector-based gene therapy has made consistent advancements in the field of oncology. Various viral vectors have been developed for use in cancer treatment and prevention. The increase in the incidence of cancer worldwide and the availability of sophisticated healthcare facilities are important factors in the market's expansion. Suicide gene therapy, oncolytic virotherapy, anti-angiogenesis, and therapeutic gene vaccines are just a few of the gene therapy treatments that have been developed to treat a variety of tumors. These treatments are all based on viral vectors. The market is expected to expand due to a rise in the incidence of cancer worldwide. The prospect for the development of novel goods is growing due to the rising research and development efforts for the creation of viral vector vaccines or treatments.

Growth Drivers

Surging Demand for Effective Therapeutics for Cancer

The main drivers behind significant research and development investments in the field of cancer therapeutics based on viral vectors are the surge in demand for the development of effective therapeutics for cancer management, the existence of a prompt approval process, and the prospects of novel drugs for significant product developments. This has a beneficial impact on the growth of the cancer category, which is predicted to accelerate the market's growth.

Restraints

Stringent Regulations

The implementation of extremely sophisticated methods has been brought about by the requirement for clinical-grade, thoroughly polished final goods. The initial set of production units for such advanced technological methods costs the viral vector companies a lot of money. The primary barrier to the rapid development of viral vectors for varied purposes is still the strict government requirements for sanctioning any new development related to the healthcare sector. The global viral vector development market's expansion is undoubtedly constrained by the lack of enough good laboratories for the testing and approval of essential raw materials.

Segmental Coverage

Global Viral Vector Manufacturing Market - By Type

The Adeno-Associated Virus (AAV) market segment holds the highest market share, due to the development of gene therapy treatments for orthopedic and ophthalmic conditions that are more effective and efficient. AAV usage has recently increased significantly across various therapeutic domains, leading to a large increase in adoption rate over the course of the projection period. Additionally deemed safe are adenoviral vectors. As a result, they are increasingly utilized in a range of research scenarios. ADV vectors are frequently used as vaccines because of their capacity to significantly stimulate humoral and T-cell immune responses. Numerous human cells' host genomes have successfully had genes disrupted in experiments using an adenovirus vector as a CRISPR/Cas9 delivery mechanism.

Global Viral Vector Manufacturing Market- By Workflow

Due to the extremely intricate processes used to polish and purify clinical grade end goods, the downstream processing sector had the highest market share. Additionally, there is a greater need for improving downstream processing as a result of the rising demand for viral vectors as a result of their expanded use as treatments. Small-scale virus preparation techniques frequently involve steps that are sophisticated and challenging to scale up. In order to ensure the amount of viruses combined with enhanced quality, numerous scalable commercial procedures are being researched and refined, and these elements are fueling the segment market growth.

Global Viral Vector Manufacturing Market - By Application

The segment for vaccinations holds the highest market share in the Global Viral Vector Manufacturing Market by application. This is a result of viral vectors' widespread use in vaccine development due to advantages associated with efficiency. Positives include the capacity to elicit a broad immunological response, as well as the safety profiles and simplicity of production. Additionally, because AAV may express episomal genes without integrating into the host genome, EMA has approved its use in clinical settings. The planning and optimization of vaccination schedules would also encourage the creation of novel vaccines.

Global Viral Vector Manufacturing Market - By End User

Due to the high demand for viral vectors for conducting research, it is anticipated that the growing involvement of scientific communities in gene and cell therapy research would boost the demand for viral vectors. In addition, the market for viral vectors and plasmid DNA synthesis is seeing the emergence of research institutions, pharmaceutical, and biopharmaceutical firms as major end-users, which is helping to drive the development of sophisticated drugs and an increasing number of gene therapy-based R&D initiatives. One of these companies, Abeona Therapeutics, for instance, is exploring AAV9-based gene therapies for CLN1 and CLN3 illnesses. It will therefore encourage market expansion.

Global Viral Vector Manufacturing Market - By Diseases

The cancer segment holds the highest market share in the global viral vector manufacturing market by diseases. The market segment expanded as a result of several research initiatives, an increase in the use of vectors for the creation of cancer medicines, and recent approvals of gene therapy products. Companies currently have a strong pipeline of cancer gene therapy products, which is expected to spur market expansion over the course of the forecast period.

Impact of COVID-19 on Global Viral Vector Manufacturing Market

The COVID-19 pandemic has highlighted the significance of vaccine development for the entire world's population and has positively impacted the expansion of the industry for viral vector production. Effective packaging cell line methods have been established for various viral vector systems, including Ad (adenoviruses), AAV (adeno-associated viruses), flaviviruses, and lentiviruses, due to the relative simplicity of making viral vector vaccines. Additionally, this has made it possible for vaccine candidates against COVID-19 to be produced on a wide scale quickly and effectively.

Regional Insights

North America holds the highest market share in the global viral vector manufacturing market. The existence of a sizable number of centers and institutes involved in the R&D of advanced medicines is one of the key factors that have contributed to the huge share of this regional market. The federal agencies' investments in the region's cell therapy research base are expected to boost the market's expansion in North America.

According to estimates, the Asia-Pacific region would record growth at the quickest rate due to factors including the growing patient population, rising R&D spending in this area, and others. Additionally, because the legal environment is less severe in this location, patients from western nations are flying there for stem cell therapy. Global businesses have also changed their business strategies in this region as a result of the enormous regional population and untapped potential. Additionally, this area provides reasonably priced operating & manufacturing facilities for performing research. These elements are expected to significantly contribute to the development of the stem cell sector in this area and accelerate the market's expansion.

Competitive Landscape

There are a number of major companies in the market for viral vector production, which is moderately competitive. Numerous smaller firms are also joining the industry and controlling a sizable market share as a result of the rising demand for innovative therapies to treat fatal diseases, such as cancer. AstraZeneca, Vibalogics, Danaher (Cytiva), Sanofi SA, F. Hoffmann-La Roche Ltd (Spark Therapeutics), Lonza, and Thermo Fisher Scientific Inc. are a few of the major market participants. Others include Cognate BioServices Inc. (Cobra Biologics), Finvector, Fujifilm Holdings, Corporation (Fujifilm Diosynth Biotechnologies), Kaneka Corporation.

Recent Developments

  • To increase the scope of its global contract development and manufacturing organization (CDMO), Merck launched a new viral vector contract development manufacturing facility for gene therapy in Carlsbad, California, in October 2021.

 

  • LEXEO Therapeutics and FUJIFILM Diosynth Biotechnologies formed a strategic partnership in October 2021 to facilitate the creation and manufacture of AAV-mediated gene treatments from LEXEO.

 

  • Fujifilm Corporation announced its plans in January 2021 to invest USD 40 million to build a new processing facility for the production of viral vectors and related research.

 

Scope of the Report

Attributes  Details
Years Considered Historical Data – 2018–2021 
Base Year – 2021
Estimated Year - 2022
Forecast – 2022–2028 
Facts Covered Revenues in USD million
Market Coverage North America, Europe, Asia Pacific, Latin America, Middle East and Africa 
Product Service/Segmentation By Type, By Workflow, By Application, By End User, By Diseases, By Region 
Key Players AstraZeneca, Vibalogics, Danaher (Cytiva), Sanofi SA, F. Hoffmann-La Roche Ltd (Spark Therapeutics), Lonza, Thermo Fisher Scientific Inc., Cognate BioServices Inc. (Cobra Biologics), Finvector, Fujifilm Holdings, Corporation (Fujifilm Diosynth Biotechnologies), and Kaneka Corporation.

 

By Type

  • Adenoviral Vector
  • Adeno-Associated Viral Vector
  • Lentiviral Vector
  • Retroviral Vector
  • Others

By Disease

  • Cancer
  • Genetic Disorder
  • Infectious Diseases
  • Others

By Application

  • Gene Therapy
  • Vaccinology
  • Others

By End User

  • Pharmaceutical and Biopharmaceutical Companies
  • Research Institutes
  • Others

By Region

  • North America
  • Europe
  • Asia Pacific
  • Latin America
  • Middle East and Africa
  1. Research Framework
    1. Research Objective
    2. Product Overview
    3. Market Segmentation
  2. Research Methodology
    1. Qualitative Research
      1. Primary & Secondary Research
    2. Quantitative Research
    3. Market Breakdown & Data Triangulation
      1. Secondary Research
      2. Primary Research
    4. Breakdown of Primary Research Respondents
    5. Assumption & Limitation
  3. Executive Summary
  4. Global Viral Vector Manufacturing Market Insights
    1. Industry Value Chain Analysis
    2. DROC Analysis
      1. Growth Drivers
      2. Restraints
      3. Opportunities
      4. Challenges
    3. Technological Advancement/Recent Development
    4. Regulatory Framework
    5. Porter’s Five Forces Analysis
      1. Bargaining Power of Suppliers
      2. Bargaining Power of Buyers
      3. Threat of New Entrants
      4. Threat of Substitutes
      5. Intensity of Rivalry
  5. Global Viral Vector Manufacturing Market Overview
    1. Market Size & Forecast by Value, 2018–2028
      1. By Value (USD Million)
    2. Market Share & Forecast
      1. By Type
        1. Adenoviral Vector
        2. Adeno-Associated Viral Vector
        3. Lentiviral Vector
        4. Retroviral Vector
        5. Others
      2. By Disease
        1. Cancer
        2. Genetic Disorder
        3. Infectious Diseases
        4. Others
      3. By Application
        1. Gene Therapy
        2. Vaccinology
        3. Others
      4. By End User
        1. Pharmaceutical And Biopharmaceutical Companies
        2. Research Institutes
        3. Others
      5. By Region
        1. North America
        2. Europe
        3. Asia Pacific
        4. Latin America
        5. Middle East and Africa
  6. North America Viral Vector Manufacturing Market
    1. Market Size & Forecast by Value, 2018–2028
      1. By Value (USD Million)
    2. Market Share & Forecast
      1. By Type
      2. By Disease
      3. By Application
      4. By End User
      5. By Country
        1. United States
        2. Canada
  7. Europe Viral Vector Manufacturing Market
    1. Market Size & Forecast by Value, 2018–2028
      1. By Value (USD Million)
    2. Market Share & Forecast
      1. By Type
      2. By Disease
      3. By Application
      4. By End User
      5. By Country
        1. Germany
        2. United Kingdom
        3. Italy
        4. France
        5. Spain
        6. Rest of Europe
  8. Asia Pacific Viral Vector Manufacturing Market
    1. Market Size & Forecast by Value, 2018–2028
      1. By Value (USD Million)
    2. Market Share & Forecast
      1. By Type
      2. By Disease
      3. By Application
      4. By End User
      5. By Country
        1. China
        2. India
        3. Japan
        4. South Korea
        5. Rest of Asia Pacific
  9. Latin America Viral Vector Manufacturing Market
    1. Market Size & Forecast by Value, 2018–2028
      1. By Value (USD Million)
    2. Market Share & Forecast
      1. By Type
      2. By Disease
      3. By Application
      4. By End User
      5. By Country
        1. Brazil
        2. Mexico
        3. Rest of Latin America
  10. Middle East & Africa Viral Vector Manufacturing Market
    1. Market Size & Forecast by Value, 2018–2028
      1. By Value (USD Million)
    2. Market Share & Forecast
      1. By Type
      2. By Disease
      3. By Application
      4. By End User
      5. By Country
        1. Saudi Arabia
        2. UAE
        3. South Africa
        4. Rest of Middle East & Africa
  11. Competitive Landscape
    1. List of Key Players and Their offerings
    2. Market Share Analysis, 2021
    3. Competitive Benchmarking, By Operating Parameters
    4. Key Strategic Developments (Mergers, Acquisitions, Partnerships, etc.)
  12. Impact of Covid-19 on Global Viral Vector Manufacturing Market Industry
  13. Company Profile (Company Overview, Financial Matrix, Competitive Landscape, Key Personnel, Key Competitors, Contact Address, and Strategic Outlook) **
    1. Batavia
    2. BioNTech IMFS GmbH
    3. Cobra Biologics Ltd
    4. FinVector Oy
    5. FUJIFILM Diosynth Biotechnologies
    6. Genelux Corporation
    7. Kaneka Eurogenetics S.A.
    8. Lonza Group AG
    9. MaxCyte Inc,
    10. Merck KGaA
    11. Novasep Inc
    12. Oxford BioMedica Plc
    13. Sirion-Biotech GmbH
    14. Spark Therpeutics
    15. Thermo Fisher Scientific Inc
    16. Other Prominent Players

 

  1. Key Strategic Recommendations

 

*Financial information in case of non-listed companies will be provided as per availability

**The segmentation and the companies are subjected to modifications based on in-depth secondary for the final deliverable

 

List of Figures

 

Figure 1: Global Viral Vector Manufacturing Market Segmentation

Figure 2: Global Viral Vector Manufacturing Market Industry Value Chain Analysis

Figure 3: Global Viral Vector Manufacturing Market Size, By Value (USD Million), 2018–2028

Figure 4: Global Viral Vector Manufacturing Market Share (%), By Type, By Value, 2018–2028

Figure 5: Global Viral Vector Manufacturing Market Share (%), By Disease, By Value, 2018–2028

Figure 6: Global Viral Vector Manufacturing Market Share (%), By Application, By Value, 2018–2028

Figure 7: Global Viral Vector Manufacturing Market Share (%), By End User, By Value, 2018–2028

Figure 8: Global Viral Vector Manufacturing Market Share (%), By Country, By Value, 2018–2028

Figure 9: North America Viral Vector Manufacturing Market Size, By Value (USD Million), 2018–2028

Figure 10: North America Viral Vector Manufacturing Market Share (%), By Type, By Value, 2018–2028

Figure 11: North America Viral Vector Manufacturing Market Share (%), By Disease, By Value, 2018–2028

Figure 12: North America Viral Vector Manufacturing Market Share (%), By Application, By Value, 2018–2028

Figure 13: North America Viral Vector Manufacturing Market Share (%), By End User, By Value, 2018–2028

Figure 14: North America Viral Vector Manufacturing Market Share (%), By Country, By Value, 2018–2028

Figure 15: Europe Viral Vector Manufacturing Market Size, By Value (USD Million), 2018–2028

Figure 16: Europe Viral Vector Manufacturing Market Share (%), By Type, By Value, 2018–2028

Figure 17: Europe Viral Vector Manufacturing Market Share (%), By Disease, By Value, 2018–2028

Figure 18: Europe Viral Vector Manufacturing Market Share (%), By Application, By Value, 2018–2028

Figure 19: Europe Viral Vector Manufacturing Market Share (%), By End User, By Value, 2018–2028

Figure 20: Europe Viral Vector Manufacturing Market Share (%), By Country, By Value, 2018–2028

Figure 21: Asia-Pacific Viral Vector Manufacturing Market Size, By Value (USD Million), 2018–2028

Figure 22: Asia-Pacific Viral Vector Manufacturing Market Share (%), By Type, By Value, 2018–2028

Figure 23: Asia-Pacific Viral Vector Manufacturing Market Share (%), By Disease, By Value, 2018–2028

Figure 24: Asia-Pacific Viral Vector Manufacturing Market Share (%), By Application, By Value, 2018–2028

Figure 25: Asia-Pacific Viral Vector Manufacturing Market Share (%), By End User, By Value, 2018–2028

Figure 26: Asia-Pacific Viral Vector Manufacturing Market Share (%), By Country, By Value, 2018–2028

Figure 27: Latin America Viral Vector Manufacturing Market Size, By Value (USD Million), 2018–2028

Figure 28: Latin America Viral Vector Manufacturing Market Share (%), By Type, By Value, 2018–2028

Figure 29: Latin America Viral Vector Manufacturing Market Share (%), By Disease, By Value, 2018–2028

Figure 30: Latin America Viral Vector Manufacturing Market Share (%), By Application, By Value, 2018–2028

Figure 31: Latin America Viral Vector Manufacturing Market Share (%), By End User, By Value, 2018–2028

Figure 32: Latin America Viral Vector Manufacturing Market Share (%), By Country, By Value, 2018–2028

Figure 33: Middle East & Africa Viral Vector Manufacturing Market Size, By Value (USD Million), 2018–2028

Figure 34: Middle East & Africa Viral Vector Manufacturing Market Share (%), By Type, By Value, 2018–2028

Figure 35: Middle East & Africa Viral Vector Manufacturing Market Share (%), By Disease, By Value, 2018–2028

Figure 36: Middle East & Africa Viral Vector Manufacturing Market Share (%), By Application, By Value, 2018–2028

Figure 37: Middle East & Africa Viral Vector Manufacturing Market Share (%), By End User, By Value, 2018–2028

Figure 38: Middle East & Africa Viral Vector Manufacturing Market Share (%), By Country, By Value, 2018–2028

Figure 39: Global Viral Vector Manufacturing Market Share Analysis, 2021

 

List of Tables

Table 1: Global Viral Vector Manufacturing Market Size, By Type, By Value (USD Million), 2018–2028

Table 2: Global Viral Vector Manufacturing Market Size, By Disease, By Value (USD Million), 2018–2028

Table 3: Global Viral Vector Manufacturing Market Size, By Application, By Value (USD Million), 2018–2028

Table 4: Global Viral Vector Manufacturing Market Size, By End User, By Value (USD Million), 2018–2028

Table 5: Global Viral Vector Manufacturing Market Size. By Country, By Value (USD Million), 2018–2028

Table 6: North America Viral Vector Manufacturing Market Size, By Type, By Value (USD Million), 2018–2028

Table 7: North America Viral Vector Manufacturing Market Size, By Disease, By Value (USD Million), 2018–2028

Table 8: North America Viral Vector Manufacturing Market Size, By Application, By Value (USD Million), 2018–2028

Table 9: North America Viral Vector Manufacturing Market Size, By End User, By Value (USD Million), 2018–2028

Table 10: North America Viral Vector Manufacturing Market Size (USD Million), By Country, By Value 2018–2028

Table 11: Europe Viral Vector Manufacturing Market Size, By Type, By Value (USD Million), By Value 2018–2028

Table 12: Europe Viral Vector Manufacturing Market Size, By Disease, By Value (USD Million), By Value 2018–2028

Table 13: Europe Viral Vector Manufacturing Market Size, By Application, By Value (USD Million), By Value 2018–2028

Table 14: Europe Viral Vector Manufacturing Market Size, By End User, By Value (USD Million), By Value 2018–2028

Table 15: 40 Europe Viral Vector Manufacturing Market Size (USD Million), By Country, By Value 2018–2028

Table 16: Asia-Pacific Viral Vector Manufacturing Market Size, By Type, By Value (USD Million), By Value 2018–2028

Table 17: Asia-Pacific Viral Vector Manufacturing Market Size (USD Million), By Type, By Value 2018–2028

Table 18: Asia-Pacific Viral Vector Manufacturing Market Size (USD Million), By Disease, By Value 2018–2028

Table 19: Asia-Pacific Viral Vector Manufacturing Market Size (USD Million), By Application, By Value 2018–2028

Table 20: Asia-Pacific Viral Vector Manufacturing Market Size (USD Million), By End User, By Value 2018–2028

Table 21: Asia-Pacific Viral Vector Manufacturing Market Size (USD Million), By Country, By Value 2018–2028

Table 22: Latin America Viral Vector Manufacturing Market Size, By Type, By Value (USD Million), By Value 2018–2028

Table 23: Latin America Viral Vector Manufacturing Market Size, By Disease, By Value (USD Million), 2018–2028

Table 24: Latin America Viral Vector Manufacturing Market Size, By Application, By Value (USD Million), 2018–2028

Table 25: Latin America Viral Vector Manufacturing Market Size, By End User, By Value (USD Million), 2018–2028

Table 26: Latin America Viral Vector Manufacturing Market Size (USD Million), By Country, By Value 2018–2028

Table 27: Middle East & Africa Viral Vector Manufacturing Market Size, By Type, By Value (USD Million), 2018–2028

Table 28: Middle East & Africa Viral Vector Manufacturing Market Size, By Disease, By Value (USD Million), 2018–2028

Table 29: Middle East & Africa Viral Vector Manufacturing Market Size, By Application, By Value (USD Million), 2018–2028

Table 30: Middle East & Africa Viral Vector Manufacturing Market Size, By End User, By Value (USD Million), 2018–2028

Table 31: Middle East & Africa Viral Vector Manufacturing Market Size (USD Million), By Country, By Value 2018–2028

Table 32: List of Key Players and Their offerings

Table 33: Competitive Benchmarking, by Operating Parameters

Table 34 Batavia Company Overview

Table 35        Batavia Financial Overview

Table 36        BioNTech IMFS GmbH Company Overview

Table 37        BioNTech IMFS GmbH Financial Overview

Table 38        Cobra Biologics Ltd Company Overview

Table 39        Cobra Biologics Ltd Financial Overview

Table 40        FinVector Oy Company Overview

Table 41        FinVector Oy Financial Overview

Table 42        FUJIFILM Diosynth Biotechnologies Company Overview

Table 43        FUJIFILM Diosynth Biotechnologies Financial Overview

Table 44        Genelux Corporation Company Overview

Table 45        Genelux Corporation Financial Overview

Table 46        Kaneka Eurogenetics S.A. Company Overview

Table 47        Kaneka Eurogenetics S.A. Financial Overview

Table 48        Lonza Group AG Company Overview

Table 49        Lonza Group AG Financial Overview

Table 50        MaxCyte Inc, Company Overview

Table 51        MaxCyte Inc, Financial Overview

Table 52        Merck KGaA Company Overview

Table 53        Merck KGaA Financial Overview

Table 54        Novasep Inc, Company Overview

Table 55        Novasep Inc Financial Overview

Table 56        Oxford BioMedica Plc Company Overview

Table 57        Oxford BioMedica Plc Financial Overview

Table 58        Sirion-Biotech GmbH Company Overview

Table 59        Sirion-Biotech GmbH Financial Overview

Table 60        Spark Therpeutics Company Overview

Table 61        Spark Therpeutics Financial Overview

Table 62        Thermo Fisher Scientific Inc Company Overview

Table 63        Thermo Fisher Scientific Inc Financial Overview

 

Market Segmentation

By Type

  • Adenoviral Vector
  • Adeno-Associated Viral Vector
  • Lentiviral Vector
  • Retroviral Vector
  • Others

By Disease

  • Cancer
  • Genetic Disorder
  • Infectious Diseases
  • Others

By Application

  • Gene Therapy
  • Vaccinology
  • Others

By End User

  • Pharmaceutical and Biopharmaceutical Companies
  • Research Institutes
  • Others

By Region

  • North America
  • Europe
  • Asia Pacific
  • Latin America
  • Middle East and Africa
No data available

To request a free sample copy of this report, please complete the form below.

We value your investment and offer free customization with every report to fulfil your exact research needs.

This website is secure and your personal details are safe.